Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa.
Samuel Terkper AhunoAnna-Lisa DoebleyThomas U AhearnJoel YarneyNicholas TitiloyeNancy HamelErnest AdjeiJoe-Nat Clegg-LampteyLawrence EduseiBaffour AwuahXiaoyu SongVerna VanderpuyeMustapha AbubakarMáire A DugganDaniel G StoverKofi NyarkoJohn M S BartlettFrances S AitpillahDaniel AnsongKevin L GardnerFelix Andy BoatengAnne M BowcockCarlos CaldasWilliam D FoulkesSeth WiafeBeatrice Wiafe-AddaiMontserrat Garcia-ClosasAlexander KwartengGavin HaJonine D FigueroaPaz Polaknull nullPublished in: NPJ precision oncology (2021)
Circulating tumor DNA (ctDNA) sequencing studies could provide novel insights into the molecular pathology of cancer in sub-Saharan Africa. In 15 patient plasma samples collected at the time of diagnosis as part of the Ghana Breast Health Study and unselected for tumor grade and subtype, ctDNA was detected in a majority of patients based on whole- genome sequencing at high (30×) and low (0.1×) depths. Breast cancer driver copy number alterations were observed in the majority of patients.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- copy number
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- mitochondrial dna
- public health
- peritoneal dialysis
- single molecule
- mental health
- risk assessment
- squamous cell carcinoma
- young adults
- patient reported
- social media
- patient reported outcomes
- health information
- nucleic acid